These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 27832705)

  • 1. AAV Infection: Protection from Cancer.
    Srivastava A; Carter BJ
    Hum Gene Ther; 2017 Apr; 28(4):323-327. PubMed ID: 27832705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain.
    Broekman ML; Comer LA; Hyman BT; Sena-Esteves M
    Neuroscience; 2006; 138(2):501-10. PubMed ID: 16414198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors.
    Liu Q; Huang W; Zhang H; Wang Y; Zhao J; Song A; Xie H; Zhao C; Gao D; Wang Y
    Gene Ther; 2014 Aug; 21(8):732-8. PubMed ID: 24849042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.
    Boutin S; Monteilhet V; Veron P; Leborgne C; Benveniste O; Montus MF; Masurier C
    Hum Gene Ther; 2010 Jun; 21(6):704-12. PubMed ID: 20095819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adeno-associated virus (AAV) serotypes 2, 4 and 5 display similar transduction profiles and penetrate solid tumor tissue in models of human glioma.
    Thorsen F; Afione S; Huszthy PC; Tysnes BB; Svendsen A; Bjerkvig R; Kotin RM; Lønning PE; Hoover F
    J Gene Med; 2006 Sep; 8(9):1131-40. PubMed ID: 16810631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells.
    Xin KQ; Mizukami H; Urabe M; Toda Y; Shinoda K; Yoshida A; Oomura K; Kojima Y; Ichino M; Klinman D; Ozawa K; Okuda K
    J Virol; 2006 Dec; 80(24):11899-910. PubMed ID: 17005662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of adeno-associated virus (AAV) into the genomes of most Thai and Mongolian liver cancer patients does not induce oncogenesis.
    Schäffer AA; Dominguez DA; Chapman LM; Gertz EM; Budhu A; Forgues M; Chaisaingmongkol J; Rabibhadana S; Pupacdi B; Wu X; Bayarsaikhan E; Harris CC; Ruchirawat M; Ruppin E; Wang XW
    BMC Genomics; 2021 Nov; 22(1):814. PubMed ID: 34763675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors.
    Halbert CL; Miller AD; McNamara S; Emerson J; Gibson RL; Ramsey B; Aitken ML
    Hum Gene Ther; 2006 Apr; 17(4):440-7. PubMed ID: 16610931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in various adeno-associated viruses (AAVs) as gene therapy agents in hepatocellular carcinoma.
    Hadi M; Qutaiba B Allela O; Jabari M; Jasoor AM; Naderloo O; Yasamineh S; Gholizadeh O; Kalantari L
    Virol J; 2024 Jan; 21(1):17. PubMed ID: 38216938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors.
    Shi W; Arnold GS; Bartlett JS
    Hum Gene Ther; 2001 Sep; 12(14):1697-711. PubMed ID: 11560765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinoma.
    Wang YG; Huang PP; Zhang R; Ma BY; Zhou XM; Sun YF
    World J Gastroenterol; 2016 Jan; 22(1):326-37. PubMed ID: 26755879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.
    Janelidze S; Nordström U; Kügler S; Brundin P
    J Gene Med; 2014; 16(9-10):300-8. PubMed ID: 25303717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer.
    Zabner J; Seiler M; Walters R; Kotin RM; Fulgeras W; Davidson BL; Chiorini JA
    J Virol; 2000 Apr; 74(8):3852-8. PubMed ID: 10729159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient AAV1-AAV2 hybrid vector for gene therapy of hemophilia.
    Hauck B; Xu RR; Xie J; Wu W; Ding Q; Sipler M; Wang H; Chen L; Wright JF; Xiao W
    Hum Gene Ther; 2006 Jan; 17(1):46-54. PubMed ID: 16409124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AAV serotype 8-mediated liver specific GNMT expression delays progression of hepatocellular carcinoma and prevents carbon tetrachloride-induced liver damage.
    Fang CC; Wu CF; Liao YJ; Huang SF; Chen M; Chen YA
    Sci Rep; 2018 Sep; 8(1):13802. PubMed ID: 30217986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-efficiency transduction of liver cancer cells by recombinant adeno-associated virus serotype 3 vectors.
    Ling C; Lu Y; Cheng B; McGoogan KE; Gee SW; Ma W; Li B; Aslanidi GV; Srivastava A
    J Vis Exp; 2011 Mar; (49):. PubMed ID: 21445055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene transfer into skeletal muscle using novel AAV serotypes.
    Louboutin JP; Wang L; Wilson JM
    J Gene Med; 2005 Apr; 7(4):442-51. PubMed ID: 15517544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy.
    Chandler RJ; LaFave MC; Varshney GK; Trivedi NS; Carrillo-Carrasco N; Senac JS; Wu W; Hoffmann V; Elkahloun AG; Burgess SM; Venditti CP
    J Clin Invest; 2015 Feb; 125(2):870-80. PubMed ID: 25607839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of liver-specific enhancer-promoter activity in the 3' untranslated region of the wild-type AAV2 genome.
    Logan GJ; Dane AP; Hallwirth CV; Smyth CM; Wilkie EE; Amaya AK; Zhu E; Khandekar N; Ginn SL; Liao SHY; Cunningham SC; Sasaki N; Cabanes-Creus M; Tam PPL; Russell DW; Lisowski L; Alexander IE
    Nat Genet; 2017 Aug; 49(8):1267-1273. PubMed ID: 28628105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Preclinical Study in Rhesus Macaques for Cystic Fibrosis to Assess Gene Transfer and Transduction by AAV1 and AAV5 with a Dual-Luciferase Reporter System.
    Guggino WB; Benson J; Seagrave J; Yan Z; Engelhardt J; Gao G; Conlon TJ; Cebotaru L
    Hum Gene Ther Clin Dev; 2017 Sep; 28(3):145-156. PubMed ID: 28726496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.